About Revalia Bio
We are scientists, surgeons, engineers, and operators united by one mission: make human biological data accessible to accelerate the medicines of tomorrow.
Our Story
Biophysicist and Revalia Bio Co-Founder Greg Tietjen worked in a lab at Yale with his Co-Founder Jenna DiRito for 11 years on organ perfusion. After learning that many donated organs could not be used for transplant, the pair were committed to finding a purpose for these organs. Revalia was born from this mission to use non-transplantable organs to accelerate research. Greg and Jenna founded the company on the premise of scalable human biological data in 2023, and we have proudly been revenue-generating since day one. As one of the first organizations to work in this space, we have attracted world-class experts to join our mission. Our team includes a transplant surgeon, researchers from Brown and Johnson & Johnson, as well as developers from Google and Amazon. We were recently awarded an ARPA-H Contract (up to $26.7 Million) to advance drug development with the Human Data Stack.
Read our latest news here.At Revalia, we believe a new model of drug and device development is needed. Our goal is to partner with researchers to shift how drugs and devices are tested because failure is unacceptable.
We believe that data integrity is an ethical obligation, and integrated human data can provide better patient relevance than traditional approaches. Revalia provides such data through the gift of organ donation.
At Revalia, we utilize donated human organs, enabling researchers to accelerate science with decision-level insights that ensure patient safety. We can deliver on our mission to honor the legacy of every donor by turning the loss of one life into knowledge that shapes the future of medicine.
Ready to accelerate your next program? Schedule a meeting with our team to explore how Human Data Trials can transform your pipeline.